Haematological cancer: Lenalidomide maintenance-perils of a premature denouement

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Of three randomized trials testing lenalidomide maintenance in myeloma, a survival benefit is apparent in one. An increased risk of second cancers is seen in all three trials. Maintenance must be considered after a review of risks and benefits, but it is premature to recommend lenalidomide maintenance for all patients.

Original languageEnglish (US)
Pages (from-to)372-374
Number of pages3
JournalNature Reviews Clinical Oncology
Issue number7
StatePublished - Jul 1 2012

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Haematological cancer: Lenalidomide maintenance-perils of a premature denouement'. Together they form a unique fingerprint.

Cite this